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Esters of quinoxaline-7-carboxylate-1,4-di-N-oxide 
as Trichomonas vaginalis triosephosphate isomerase inhibitors
Trichomoniasis is a public health problem world-
wide. Trichomoniasis treatment consists of the use 
of nitroimidazole derivatives; however, therapeu-
tic ineffectiveness occurs in 5 to 20 % of the cases. 
Therefore, it is essential to propose new pharma-
cological agents against this disease. In this work, 
esters of quinoxaline-7-carboxylate-1,4-di-N-oxide 
(EQX-NO) were evaluated in in vitro assays as  novel 
trichomonicidal agents. Additionally, an in vitro 
enzyme assay and molecular docking analysis 
against triosephosphate isomerase of Trichomonas 
vaginalis to confirm their mechanism of action 
were performed. Ethyl (compound 12) and n-pro-
pyl (compound 37) esters of quinoxaline-7-carboxy-
late-1,4-di-N-oxide derivatives showed tricho-
monicidal activity comparable to nitazoxanide, 
whereas five methyl (compounds 5, 15, 19, 20 and 
22), four isopropyl (compounds 28, 29, 30 and 34), 
three ethyl (compounds 4, 13 and 23) and one n-
propyl (compound 35) ester derivatives displayed 
activity comparable to albendazole. Compounds 6 
and 20 decreased 100 % of the enzyme activity of 
recombinant protein triosephosphate isomerase.
Keywords: quinoxaline 1,4-di-N-oxide, trichomo-
niasis, triosephosphate isomerase inhibitor
Trichomonas vaginalis (T. vaginalis) is a protozoon that poses an important public health 
challenge (1–3). It colonizes the human urogenital tract by adhering to the epithelium. 
T. vaginalis infection is often asymptomatic but can produce inflammation of the urinary 
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tract. Trichomoniasis is a non-viral sexually diffused infection that affects approximately 
276 million people per year (4, 5).
The drug of choice for trichomoniasis is metronidazole, a 5-nitroimidazole derivative 
(5); however, it causes severe adverse effects since it is carcinogenic and teratogenic (6). 
These effects have been associated with prolonged treatment or high doses (7, 8). Addition-
ally, the expansion of resistant T. vaginalis strains makes new antitrichomoniasis agents 
necessary.
Quinoxaline (QX) is a privileged structure for the design and development of new 
antibacterial (9), anticancer (10), and antiparasitic (11) agents with some derivatives in the 
clinical phase studies (12, 13). Interestingly, quinoxaline 1,4-di-N-oxide (QX-NO) deriva-
tives show biological effects against diverse protozoa (14–17); however, QX-NO has not 
been evaluated against T. vaginalis. Therefore, in this work, the esters of quinoxaline-7-car-
boxylate-1,4-di-N-oxide (EQX-NO) derivatives were evaluated as novel antitrichomoniasis 
agents. Furthermore, in silico and in vitro analyses were done against T. vaginalis triosephos-
phate isomerase to elucidate their mechanism of action.
EXPERIMENTAL
Syntheses
All EQX-NO derivatives were synthesized using the method reported by Gomez-Caro 
et al. (18). All molecules were identified by IR spectroscopy, 1H NMR and elemental analy-
sis of C, H and N (see Table SI, Supplementary material), as in previous research (14, 15, 17, 
18).
In vitro evaluation against T. vaginalis
T. vaginalis strain GT3 (a wild strain isolated in Centro Medico Nacional Siglo XXI, 
Instituto Mexicano del Seguro Social, Mexico) was used. EQX-NO derivatives, albendazole 
(ABZ), metronidazole (MTZ), and nitazoxanide (NTZ) were tested against T. vaginalis 
strain GT3 in vitro using the previously reported method (19). Dimethylsulfoxide (DMSO) 
was used as a negative control. The half-maximal inhibitory concentration (IC50) was cal-
culated using the Probit analysis. 
In silico procedures
Protein structure. – The atomic coordinates of triosephosphate isomerase (TIM) from T. 
vaginalis (TvTIM) from the Protein Data Bank (PDB, code 3QSR) were used with Molecular 
Operating Environment (MOE) software and CHARMM27 force field (20, 21). This struc-
ture was used to predict binding free energy (ΔGbind) values between TvTIM and EQX-NO 
derivatives. Site Finder implemented in the MOE was used to determine potential binding 
sites (22, 23).
Molecular docking. – For molecular docking, the receptor (TIM, 3QSR) was kept inflex-
ible, while examining twenty conformations for each of the ligands. All crystallographic 
water molecules were deleted from the initial structures. Molecular docking was done 
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with the MOE software using the previously reported procedure (24, 25). The molecules 
were analyzed on twenty-three potential binding sites from TvTIM (Table SII, Supplemen-
tary material) to propose a potential interaction site that explains the effect on enzyme 
activity.
To describe the interaction of the ligands, the binding affinity of each complex was 
estimated with the generalized Born/volume integral ratio (GB/VI) using parameters in 
MOE (26). The generalized Born or non-bonded interaction energies comprised van der 
Waals, Coulomb electrostatic interactions, and implied solvent interaction energies.
In vitro assays against TvTIM
Stock solutions of EQX-NO derivatives were prepared in DMSO (1 %) and further dilu-
ted with media to obtain 50 and 100 µg µL–1 of each compound tested. Recombinant TvTIM 
was obtained as previously described (27, 28). The conversion of glyceraldehyde 3-phos-
phate (GAP) into dihydroxyacetone phosphate was followed to determine enzyme activity 
following a previous procedure (29–35).
RESULTS AND DISCUSSION
Methyl (m-), ethyl (e-), isopropyl (i-), and n-propyl (np-) EQX-NO derivatives were ob-
tained (see Supplementary material) (18) and evaluated in vitro against T. vaginalis. Table I 
shows their trichomonicidal activity.
Trichomonicidal activity
Among m- and e-EQX-NO derivatives, twelve compounds had an IC50 between 1 and 
10 µmol L–1, and seven compounds had a higher IC50 value than ABZ (Table I). However, 
none of the m- and e-EQX-NO derivatives had trichomonicidal activity greater than MTZ 
and NTZ. Only compound 12, an ethyl methyl-3-methyl-quinoxaline-2,7-dicarboxylate-1,4-
di-N- oxide, had IC50 of 0.97 µmol L–1, a value comparable or equal to both reference drugs 
(MTZ and NTZ). In general, the structure-activity relationship (SAR) analysis showed that 
aliphatic, ethoxy and methoxy groups at R1-position on the QX ring enhance biological 
effects. Additionally, the steric effect at R1-position is a key factor in the activity. A trifluoro-
methyl and a methyl group at R2- and R3-position, resp., also showed trichomonicidal 
activity. 
None of the five np-EQX-NO derivatives showed trichomonicidal activity, but two 
compounds had IC50 values from 5.0 to 6.2 µmol L–1, whereas two more had an IC50 value 
< 3 µmol L–1 (Table I). Compounds 35 (n-propyl methyl-3-methylquinoxaline-2,7-dicarboxy-
late-1,4-di-N-oxide) and 37 (n-propyl ethyl-3-methylquinoxaline-2,7-dicarboxylate-1,4-di- 
-N-oxide) showed better trichomonicidal activity than ABZ. Both compounds have an ester 
and methyl group at R1- and R2-position, resp., on the QX-NO ring. Additionally, com-
pound 37 showed activity comparable to NTZ.
From i-EQX-NO derivatives, nine compounds showed no trichomonicidal activity 
(IC50 > 10 µmol L–1) and eight compounds had an IC50 value from 2.9 to 6.4 µmol L–1. 
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Compd. R1 R2 R3 IC50 (µmol L–1)a
1 C6H5 CH3 CH3 > 10
2 C6H5 CH3 CH3CH2 > 10
3 CH3 CF3 CH3CH2 > 10
4 C10H7 CF3 CH3CH2 3.52 ± 0.07
5 C4H3S CF3 CH3 2.63 ± 0.01
6 C4H3S CF3 CH3CH2 > 10
7 NHC6H5 CH3 CH3 > 10
8 OCH2CH3 CH3 CH3 > 10
9 OCH2CH3 CH3 CH3CH2 5.93 ± 0.23
10 C6H5 CF3 CH3 5.32 ± 0.12
11 OCH3 CH3 CH3 6.19 ± 0.32
12 OCH3 CH3 CH3CH2 0.97 ± 0.04
13 CH2CH3 CF3 CH3CH2 2.51 ± 0.09
14 C6H5Cl CF3 CH3CH2 > 10
15 C10H7 CF3 CH3 4.29 ± 0.12 
16 C4H3O CF3 CH3 > 10
17 CH3 CH3 CH3 > 10
18 OCH2CH3 CH2COOCH2CH3 CH3 > 10
19 CH2CH3 CF3 CH3 3.25 ± 0.05
20 CH(CH3)2 CF3 CH3 4.01 ± 0.11
21 OCH2C6H5 CH3 CH3 > 10
22 OCH2CH3 C6H5 CH3 2.55 ± 0.03
23 OCH2CH3 C6H5 CH3CH2 2.92 ± 0.01
24 NH2 CH3 CH3CH2 6.00 ± 0.04
25 OCH3 CH3 (CH3)2CH > 10
26 OCH2CH3 CH3 (CH3)2CH > 10
27 OC(CH3)3 CH3 (CH3)2CH > 10
28 OCH2CH3 CH2COOCH2CH3 (CH3)2CH 3.50 ± 0.12
29 C4H3S CF3 (CH3)2CH 3.68 ± 0.04
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 Although five compounds had lower IC50 values (< 4.0 µmol L–1) than ABZ, none showed 
better trichomonicidal activity than MTZ and NTZ (Table I).
Finally, the N-oxide groups on the QX ring from some EQX-NO derivatives were elimi-
nated (by reduction with sodium dithionite) to determine their effect on trichomonicidal 
activity (Table I). EQX-NO derivatives 10, 12, and 20 with trichomonicidal activity below 
Compd. R1 R2 R3 IC50 (µmol L–1)a
30 CH3 CF3 (CH3)2CH 3.77 ± 0.02
31 C6H5 CF3 (CH3)2CH 5.25 ± 0.01
32 C10H7 CF3 (CH3)2CH 5.41 ± 0.01
33 C4H3O CF3 (CH3)2CH > 10
34 CH(CH3)2 CF3 (CH3)2CH 3.21 ± 0.07
35 OCH3 CH3 CH3CH2CH2 2.56 ± 0.11
36 C4H3S CF3 CH3CH2CH2 5.04 ± 0.12
37 OCH2CH3 CH3 CH3CH2CH2 1.46 ± 0.01
38 C(CH3)3 CH3 CH3CH2CH2 > 10
39 NHC6H5 CH3 (CH3)2CH > 10
40 C6H5 CH3 (CH3)2CH 6.46 ± 0.08
41 C(CH3)3 C(CH3)3 (CH3)2CH > 10
42 NH2 CH3 (CH3)2CH > 10
43 C4H3O CF3 CH3CH2CH2 > 10
44 OCH2CH3 CF3 (CH3)2CH 2.98 ± 0.07
45 C(CH3)3 CF2CF2CF3 (CH3)2CH > 10
46 CF2CF3 CF3 (CH3)2CH > 10
47 OCH2CH3 CF3 CH3CH2CH2 > 10
48 NHC6H5 CH3 CH3CH2CH2 > 10
49 CH3 CH3 CH3CH2CH2 6.24 ± 0..41
50 NH2 CH3 CH3CH2CH2 > 10
51b OCH3 CH3 CH2CH3 > 10
52b C6H5 CF3 CH3 4.94 ± 0.12
53b CH(CH3)2 CF3 CH3 > 10
ABZ 4.08 ± 0.21
MTZ 0.69 ± 0.01
NTZ 1.00 ± 0.05
ABZ – albendazole, MTZ – metronidazole, NTZ – nitazoxanide
a Mean ± SD of triplicate determinations.
b Quinoxaline derivatives without N-oxide groups.
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6.0 µmol L–1 were selected to obtain QX derivatives 51, 52, and 53 (see Supplementary 
material), resp. These new compounds showed no or low biological activity, except com-
pound 52 (methyl 2-benzoyl-3-trifluoromethyl quinoxaline-7-carboxylate), which had an 
antiprotozoal effect against T. vaginalis. These results show that the N-oxide groups are the 
key factor for the trichomonicidal activity and suggest that compound 52 has a different 
mechanism of action than EQX-NO derivatives. Still, the mechanism of action of QX-NO is 
currently not clear, as reported by Cheng et al. (12).
Enzymatic activity of TvTIM
Previously, Guzman et al. (32), reported that QX-NO derivatives affect the enzymatic 
activity of Trypanosoma cruzi TIM. Therefore, in this work, TvTIM was considered a poten-
tial drug target. All EQX-NO derivatives were evaluated in enzyme activity assays, but 
only four compounds (6, 10, 20 and 42) decreased TvTIM activity to some degree. The effect 
of compounds 6 (ethyl 2-(thiophene-2-carbonyl)-3-trifluoromethylquinoxaline-7-car-
boxylate-1,4-di-N-oxide), 10 (methyl 2-benzoyl-3-trifluoromethylquinoxaline-7-carboxyl-
Fig. 1. The main interaction site on TvTIM for the compounds 6, 10, 20, and 42. Residues Lys11, His94, 
and Glu166 (red color) and seven conformers of each compound (pink color).
Table II. Effect of EQX-NO derivatives against the enzymatic activity of TvTIM, predictive binding free 
energy value and main residues in the interaction on the active site
Compd.
TvTIM enzymatic activity (%)a ΔGbind 
(kcal mol–1)
Main amino acids in the 
interactions50 g L–1 100 g L–1
6 49.6 ± 4.1 0 –0.6 Glu166
10 69.0 ± 4.5 38.3 ± 3.2 –7.3 Lys11, Gly172, and Ser212
20 49.6 ± 2.5 0 –3.2 Lys11, Ile171, and Gly172
42 51.6 ± 4.1 30.3 ± 4.0 –4.7 Lys11, Ala170, Ile171, and Gly172
ΔGbind – binding free energy
a Mean ± SD of triplicate determinations.
491
I. Palos et al.: Esters of quinoxaline-7-carboxylate-1,4-di-N-oxide as Trichomonas vaginalis triosephosphate isomerase inhibitors, Acta 
Pharm. 71 (2021) 485–495.
 
ate-1,4-di-N-oxide), 20 (ethyl methyl-3-methyl-quinoxaline-2,7-dicarboxylate-1,4-di-N-ox-
ide), and 42 (isopropyl 2-amide-3-methyl-quinoxaline-7-carboxylate-1,4-di-N-oxide) on the 
activity of TvTIM was determined in two concentrations (50 and 100 µg µL–1). The results 
are displayed in Table II. Three of the abovementioned EQX-NO derivatives (6, 20, and 42) 
showed similar enzyme activity inhibition (50 % approx.) at 50 µg µL–1, and only com-
pounds 6 and 20 showed 100 % enzyme inhibition at 100 µg µL–1. These compounds caused 
a decrease in the function of TvTIM at higher concentrations than the other reported com-
pounds (34–36). Nevertheless, this is the first report that shows that EQX-NO derivatives 
have an inhibitory effect against TvTIM. Previously, Cheng et al. (12) mentioned two sulf-
oxide QX-NO derivatives with a better trichonomicidal activity than metronidazole, how-
ever, the mechanism of action was not explored. Therefore, QX-NO derivatives are a new 
option to develop new TvTIM inhibitors.
Fig. 2. Interaction site between EQX-NO derivatives and the potential active site of TvTIM. a) com-
pound 6, b) compound 10, c) compound 20, and d) compound 42.
a)                                                                              b)
c)                                                                              d)
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Molecular docking analysis on TvTIM
Molecular docking analysis was done to describe the molecular interaction of the EQX-
NO derivatives on 23 potential TvTIM binding sites (Table SII, Supplementary material).
The compounds that affected the enzymatic activity (6, 10, 20, and 42) showed the best 
interactions with Lys11, His94, and Glu166, among other residues, near the active site (Fig. 1). 
The best interactions for the four compounds were determined in the region of residues near 
Lys11, His94, Glu166, Ala170, Ile171, Gly172, and Ser212 (Fig. 2). Additionally, predictive 
ΔGbind was determined (Table II). Compound 10 showed the lowest ΔGbind value 
(–7.3 kcal mol–1); however, this compound showed the lowest enzyme inhibition (31 %) at 50 
µg µL–1. The other three compounds (6, 20, and 42) showed very different ΔGbind values but 
comparable enzyme inhibition. These results suggest no correlation between in vitro and in 
silico analysis. Therefore, compounds 6, 10, 20, and 42 could be interacting on another bind-
ing site of TvTIM, causing an effect on the enzyme activity assays. The molecular docking 
results from the other QX-NO derivatives showed a probable interaction in the interface and 
core of TvTIM, which can be related to not affecting the enzymatic activity of TvTIM.
CONCLUSIONS
Four different types of EQX-NO derivatives were tested as novel agents against T. vagi-
nalis. e-EQX-NO derivatives showed a better trichomonicidal effect than BZN. In particular, 
compound 12 (ethyl methyl-3-methyl-quinoxaline-2,7-dicarboxylate-1,4-di-N-oxide) in vitro 
assays show a better trichomonicidal activity than ABZ and NTZ. Additionally, four com-
pounds 6 (ethyl 2-(thiophene-2-carbonyl)-3-trifluoromethylquinoxaline-7-carboxylate-1,4-di- 
-N-oxide), 10 (methyl 2-benzoyl-3-trifluoromethylquinoxaline-7-carboxylate-1,4-di-N-oxide), 
20 ( ethyl methyl-3-methyl-quinoxaline-2,7-dicarboxylate-1,4-di-N-oxide), and 42 (isopropyl 
2-amide-3-methyl-quinoxaline-7-carboxylate-1,4-di-N-oxide) reduced the enzymatic activity 
of recombinant protein TvTIM. SAR analysis showed that methyl and ethyl groups at R3-
position and N-oxide groups on the QX ring are the key moieties for the biological activity. 
Molecular docking analysis revealed that the main interaction site of these compounds is 
near to the active site where they interact with Lys11, Glu166, Ala170, Ile171, and Gly172. 
Therefore, these types of compounds could help in the development of new and more effective 
TvTIM inhibitors to combat the T. vaginalis resistance.
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